The ADX71441 compound, analyzed in female guinea pigs with bladder overactivity, induced an increase in inter contraction interval, a validated measure of bladder muscle control, in the first 15 minutes post-administration compared to vehicle.
The efficacy of ADX71441 was well correlated with its pharmacokinetic properties and also decreased micturition (urination) frequency compared to vehicle at the 1mg/kg dose, the company said.
In an independent mouse diuretic stress-induced model of overactive bladder, administration of ADX71441 dose-dependently normalized urination latencies and also dose-dependently reduced micturition frequency in furosemide-treated animals.
The magnitude of the effect in response to 10mg/kg ADX71441 was similar to those observed in oxybutynin treated animals.
Addex president and CEO Bharatt Chowrira said: "These data along with our recent announcement of positive phase 2 data in Parkinson’s disease levodopa-induced dyskinesia demonstrate the strength of our pipeline based on allosteric modulator oral small molecule platform and its ability to generate multiple high value novel product opportunities."